A new study published in the Journal of Chromatography B highlights a rigorous approach to identifying and quantifying ...

Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

As part of the DSE-K12 Launch Collective, Colleen Smyth BA’15 MS’21 strives to bring data science education to more students.

Blood biomarkers at disease onset may help predict relapse-associated worsening and progression independent of relapse ...